Cited by 216Curcumin's Biomedical ApplicationsTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.

Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study

Lopresti, Adrian L., Maes, Michael, Maker, Garth L., Hood, Sean D., Drummond, Peter D.·2014·Journal of Affective Disorders

DOI 10.1016/j.jad.2014.06.001

Open this paper in CoChat — free account

Abstract

Background Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the treatment of depressive symptoms in individuals with major depressive disorder.Methods In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI).Results From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.Conclusions Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.Limitations Investigations with larger sample sizes, over extended treatment periods, and with varying curcumin dosages are required.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2014.06.001

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Using multivariate statistics
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 79,882
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
State‐Trait Anxiety Inventory
Spielberger, C. D. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0943 · Cited by 2,535
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases
Aggarwal, B. B., & Harikumar, K. B. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.06.010 · Cited by 2,139
Curcumin: The story so far
Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.009 · Cited by 1,701
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
TRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
The inventory for depressive symptomatology (IDS): Preliminary findings
Rush, A. J., Giles, D. E., Schlesser, M. A., Fulton, C. L., Weissenburger, J. E., & Burns, C. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90060-0 · Cited by 908
Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression
Leonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Self-citation
Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment
Basnet, P., & Škalko‐Basnet, N. (2011) · Molecules · doi:10.3390/molecules16064567 · Cited by 750
The Targets of Curcumin
Zhou, H., Beevers, C. S., & Huang, S. (2011) · Current Drug Targets · doi:10.2174/138945011794815356 · Cited by 729
The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Self-citation
Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression
Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex
Plummer, S. M., Holloway, K., Manson, M. M., Munks, R. J. L., Kaptein, A., Farrow, S. N., & Howells, L. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202980 · Cited by 627
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434
The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427
Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers
Aggarwal, B. B., Gupta, S. C., & Sung, B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12131 · Cited by 401
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O. M., Drexhage, H. A., McNeil, J. J., Moylan, S., O'Neil, A. E., Davey, C. G., Sanna, L., & Maes, M. H. J. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 395
Self-citation
Antidepressant activity of curcumin: involvement of serotonin and dopamine system
Kulkarni, S. K., Bhutani, M. K., & Bishnoi, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1300-y · Cited by 339
Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis
Sahebkar, A. (2013) · Phytotherapy Research · doi:10.1002/ptr.5045 · Cited by 310
Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB
Xu, Y., Ku, B., Tie, L., Yao, H., Jiang, W., Ma, X., & Li, X. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.009 · Cited by 298
Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats
Xu, Y., Ku, B., Cui, L., Li, X.-J., Barish, P. A., Foster, T. C., & Ogle, W. O. (2007) · Brain Research · doi:10.1016/j.brainres.2007.05.071 · Cited by 292
Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes
Bhutani, M. K., Bishnoi, M., & Kulkarni, S. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.10.007 · Cited by 249
Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients.
Belcaro, G., Cesarone, M. R., Dugall, M., PELLEGRINI, L., Ledda, A. G., Grossi, M. G., Togni, S., & Appendino, G. (2010) · PubMed · Cited by 241
Efficacy and Safety of Curcumin in Major Depressive Disorder: A Randomized Controlled Trial
Sanmukhani, J., Satodiya, V., Trivedi, J. S., Patel, T. K., Tiwari, D., Panchal, B. N., Goel, A., & Tripathi, C. B. (2013) · Phytotherapy Research · doi:10.1002/ptr.5025 · Cited by 218
Serotonin and depression: pathophysiological mechanism or marketing myth?
Cowen, P. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.004 · Cited by 218
Zur Kenntnis des Curcumins
Miłobedzka, J., Kostanecki, S. V., & Lampe, V. (1910) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.191004302168 · Cited by 203
Assessment of State and Trait Anxiety in Subjects with Anxiety and Depressive Disorders
Kennedy, B. L., Schwab, J. J., Morris, R. L., & Beldia, G. (2001) · Psychiatric Quarterly · doi:10.1023/a:1010305200087 · Cited by 198
Antioxidants as Antidepressants
Scapagnini, G., Davinelli, S., Drago, F., LORENZO, A. D., & Oriani, G. (2012) · CNS Drugs · doi:10.2165/11633190-000000000-00000 · Cited by 188
Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress
Rai, B., Kaur, J., Jacobs, R., & Singh, J. (2010) · Journal of Oral Science · doi:10.2334/josnusd.52.251 · Cited by 186
Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review
Fond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 175
Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property
Suresh Ramnath, N. A. I. K., Thakare, V. N., & Patil, S. R. (2010) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.03.001 · Cited by 168
Neuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167
Content Validity of the Psychiatric Symptom Index, CES-Depression Scale, and State-Trait Anxiety Inventory from the Perspective of DSM-IV
Okun, A., Stein, R. E. K., Bauman, L. J., & Silver, E. J. (1996) · Psychological Reports · doi:10.2466/pr0.1996.79.3.1059 · Cited by 162
Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458732 · Cited by 151
Self-citation
Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats
Li, Y., Wang, F., Pan, Y., Qiang, L.-Q., Cheng, G. S., Zhang, W., & Kong, L. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.01.006 · Cited by 136
How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
Andrade, C., & Rao, N. K. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.74318 · Cited by 133
Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats
Huang, Z., Zhong, X., Li, Z., Feng, C.-R., Pan, A.-J., & Mao, Q. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.02.030 · Cited by 132
Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test
Xia, X., Cheng, G., Pan, Y., Xia, Z. H., & Kong, L. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.09.042 · Cited by 128
Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats
Zhang, L., Luo, J., Zhang, M., Yao, W., Ma, X., & Yu, S. Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001661 · Cited by 116
Antidepressant-like effects of curcumin in chronic mild stress of rats: Involvement of its anti-inflammatory action
Jiang, H., Wang, Z., Wang, Y., Xie, K., Zhang, Q., Luan, Q., Chen, W., & Liu, D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.009 · Cited by 113
The structure and dimensionality of the Inventory of Depressive Symptomatology Self Report (IDS-SR) in patients with depressive disorders and healthy controls
Wardenaar, K. J., van Veen, T., Giltay, E. J., den Hollander-Gijsman, M. E., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.020 · Cited by 95
Curcumin as an Add-On to Antidepressive Treatment
Bergman, J., Miodownik, C., Bersudsky, Y., Sokolik, S., Lerner, P. P., Kreinin, A., Polakiewicz, J., & Lerner, V. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31828ef969 · Cited by 92
C-reactive protein is elevated in atypical but not nonatypical depression: Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004
Hickman, R. J., Khambaty, T., & Stewart, J. C. (2014) · Journal of Behavioral Medicine · doi:10.1007/s10865-013-9510-0 · Cited by 90
IDS-C and IDS-SR: Psychometric properties in depressed in-patients
Corruble, E., Legrand, J. M., Duret, C., Charles, G., & Guelfi, J. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00055-5 · Cited by 89
Clinical Patterns and Treatment Outcome in Patients with Melancholic, Atypical and Non-Melancholic Depressions
Gili, M., Roca, M., Armengol, S., Asensio, D., García‐Campayo, J., & Parker, G. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048200 · Cited by 87
Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice
Abdel-Wahab, B. A., & Salama, R. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.07.015 · Cited by 86
The role of anti-inflammatory treatment in psychiatric disorders.
Müller, N. (2013) · PubMed · Cited by 82
New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio
Kocki, T., Wnuk, S., Kloc, R., Kocki, J., Owe‐Larsson, B., & Urbańska, E. M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0668-8 · Cited by 72
Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
Sanmukhani, J., Anovadiya, A., & Tripathi, C. B. (2011) · PubMed · Cited by 69
Loneliness and locus of control for alcoholic males: Validity against Murray need and Cattell trait dimensions
Nerviano, V. J., & Gross, W. F. (1976) · Journal of Clinical Psychology · doi:10.1002/1097-4679(197604)32:2 · Cited by 55
Review of the Use of Pattern Analysis to Differentiate True Drug and Placebo Responses
Rothschild, R., & Quitkin, F. M. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288625 · Cited by 34
Comprehensive Bibliography
Daviau, P. M. M. (2016) · BRILL eBooks · doi:10.1163/9789004316201_012 · Cited by 28
A Curcumin Derivative, 2,6-Bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) Attenuates Prostaglandin E2 Synthesis via Selective Suppression of Cyclooxygenase-2 in IFN-g/LPS-Stimulated Macrophages
Lee, K.-H., Abas, F., Alitheen, N. B., Shaari, K., Lajis, N. H., & Ahmad, S. (2011) · Molecules · doi:10.3390/molecules16119728 · Cited by 23
The inventory of depressive symptomatology (IDS): validityand reliability of clinician (IDS-C30) and self-report form(IDS-SR30) in patients with major depressive disorder -
Aslan, S., Kuruoğlu, A., Ișıklı, S., Rush, A. J., Taner, E., & Işık, E. (2006) · Psychiatry and Clinical Psychopharmacology · Cited by 2

Flagged first, then by citations

2 of the 62 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Milobedzka, 1910, Structure of curcumin, Ber. Dtsch. Chem. Ges., 43, 2163

Sorted by citations

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13621 · Cited by 1,068
Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – A review
Amalraj, A., Pius, A., Gopi, S., & Gopi, S. (2016) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2016.05.005 · Cited by 976
Turmeric ( Curcuma longa ) and its major constituent (curcumin) as nontoxic and safe substances: Review
Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018) · Phytotherapy Research · doi:10.1002/ptr.6054 · Cited by 556
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R. K., Raghuwanshi, R., & Jain, P. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 529
The therapeutic potential of curcumin: A review of clinical trials
Salehi, B., Stojanović-Radić, Z. Z., Matejić, J. S., Sharifi‐Rad, M., Kumar, N. V. A., Martins, N. A., & Sharifi‐Rad, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.016 · Cited by 497

See all 216

Authors: Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D.
Affiliations: Murdoch University (AU)
Deakin University (AU)
The University of Western Australia (AU)
Corresponding author: Lopresti, Adrian L.
ORCID: Lopresti, Adrian L.
Maes, Michael
Maker, Garth L.
Hood, Sean D.
Drummond, Peter D.
Venue: Journal of Affective Disorders
Publisher: Elsevier BV
Published: 2014-10
Volume: 167
Pages: 368-375
ISSN: 0165-0327 (ISSN-L)
DOI: 10.1016/j.jad.2014.06.001
OpenAlex: W2048063648
Cited by: 216
References: 62
Citations by year: 2026: 22 · 2025: 16 · 2024: 16 · 2023: 16 · 2022: 12 · 2021: 21 · 2020: 13 · 2019: 23 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 26 · 2014: 3
FWCI: 8.99
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Affective Disorders (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
Murdoch University Research Portal (submittedVersion)
Funders: Arjuna Natural Extracts Limited
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: curcumin, major depressive disorder, antidepressant effects, atypical depression, depressive symptoms, anxiety, neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal axis, turmeric, natural product therapy
MeSH terms: Adult, Affect, Antidepressive Agents, Curcumin, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Psychometrics, Surveys and Questionnaires, Western Australia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks